Identification of subgroups for escalating and de-escalating treatment in breast cancer by combined use of clinical-pathological and genomic tests

To identify potential subgroups for escalating and de-escalating treatment in breast cancer by combined use of clinical–pathological data genomic data (Copy Number Variations and epigenetic alterations).